These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23494836)

  • 1. Sorafenib in patients with refractory or recurrent multiple myeloma.
    Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
    Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib for the treatment of multiple myeloma.
    Gentile M; Martino M; Recchia AG; Vigna E; Morabito L; Morabito F
    Expert Opin Investig Drugs; 2016 Jun; 25(6):743-9. PubMed ID: 26998658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
    Smolle E; Taucher V; Petru E; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
    Srkalovic G; Hussein MA; Hoering A; Zonder JA; Popplewell LL; Trivedi H; Mazzoni S; Sexton R; Orlowski RZ; Barlogie B
    Cancer Med; 2014 Oct; 3(5):1275-83. PubMed ID: 24913924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
    Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
    Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
    Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
    Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
    Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
    Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
    Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
    Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
    Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
    Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
    Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
    Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
    Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E
    Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perforating folliculitis-like reaction related to sorafenib.
    Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
    Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
    Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
    Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.